

# Dirk J Blom

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9079614/publications.pdf>

Version: 2024-02-01

76  
papers

8,636  
citations

126907

33  
h-index

74163

75  
g-index

76  
all docs

76  
docs citations

76  
times ranked

7343  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 372, 1500-1509.	27.0	1,352
2	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2010, 375, 998-1006.	13.7	813
3	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. <i>Lancet, The</i> , 2013, 381, 40-46.	13.7	624
4	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015, 385, 341-350.	13.7	609
5	A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. <i>New England Journal of Medicine</i> , 2014, 370, 1809-1819.	27.0	607
6	Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. <i>Clinical Infectious Diseases</i> , 2021, 73, e2005-e2015.	5.8	405
7	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. <i>European Heart Journal</i> , 2015, 36, ehv370.	2.2	395
8	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. <i>New England Journal of Medicine</i> , 2019, 381, 531-542.	27.0	359
9	Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, 1186-1194.	2.2	344
10	Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). <i>Journal of the American College of Cardiology</i> , 2014, 63, 1278-1288.	2.8	316
11	Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy. <i>Circulation</i> , 2011, 124, 2202-2207.	1.6	301
12	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 280-290.	11.4	191
13	PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. <i>Journal of Lipid Research</i> , 2016, 57, 1086-1096.	4.2	180
14	Non-DNA binding, dominant-negative, human PPAR $\gamma$ mutations cause lipodystrophic insulin resistance. <i>Cell Metabolism</i> , 2006, 4, 303-311.	16.2	164
15	Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020, 75, 565-574.	2.8	126
16	Autoantibodies against GPIIb/IIIa as a Cause of Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2017, 376, 1647-1658.	27.0	112
17	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 136, 332-335.	1.6	103
18	Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020, 76, 131-142.	2.8	96

#	ARTICLE	IF	CITATIONS
19	PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo. <i>JACC Basic To Translational Science</i> , 2016, 1, 419-427.	4.1	94
20	Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International Cholesterol management Practice Study (ICLPS). <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1087-1094.	1.8	86
21	Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. <i>European Heart Journal</i> , 2018, 39, 1162-1168.	2.2	81
22	Effects of Evolocumab on Vitamin E and Steroid Hormone Levels. <i>Circulation Research</i> , 2015, 117, 731-741.	4.5	80
23	Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 592-598.	2.4	77
24	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet, The</i> , 2022, 399, 719-728.	13.7	69
25	Evaluation of the efficacy, safety and glycaemic effects of evolocumab (<scp>AMC</scp> 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 98-107.	4.4	60
26	Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2365-2373.	2.8	57
27	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 121.	1.7	48
28	Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B Concentrations. <i>Clinical Chemistry</i> , 2005, 51, 904-907.	3.2	45
29	Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). <i>Journal of Clinical Lipidology</i> , 2020, 14, 807-817.	1.5	41
30	Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1234-1243.e5.	1.5	40
31	Proprotein convertase subtilisin/kexin type 9 inhibition. <i>Current Opinion in Lipidology</i> , 2012, 23, 511-517.	2.7	38
32	Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients. <i>PLoS ONE</i> , 2016, 11, e0151911.	2.5	38
33	Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. <i>Atherosclerosis</i> , 2018, 277, 502-507.	0.8	37
34	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2017, 120, 1521-1527.	1.6	36
35	Lomitapide and Mipomersen Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. <i>Current Atherosclerosis Reports</i> , 2019, 21, 48.	4.8	36
36	LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. <i>Journal of Clinical Lipidology</i> , 2016, 10, 273-282.	1.5	35

#	ARTICLE	IF	CITATIONS
37	Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). <i>Journal of Clinical Pharmacology</i> , 2017, 57, 616-626.	2.0	32
38	Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia. <i>Journal of Lipid Research</i> , 2003, 44, 212-217.	4.2	31
39	Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 96.	2.7	31
40	Lipoprotein metabolism in familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 2021, 62, 100062.	4.2	31
41	Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2299-2300.	2.8	30
42	A Pharmacogenetic Approach to the Treatment of Patients With PPAR $\gamma$ Mutations. <i>Diabetes</i> , 2018, 67, 1086-1092.	0.6	30
43	World Heart Federation Cholesterol Roadmap. <i>Global Heart</i> , 2017, 12, 179.	2.3	30
44	Effect of Evolocumab on Lipoprotein Particles. <i>American Journal of Cardiology</i> , 2018, 121, 308-314.	1.6	29
45	Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. <i>Atherosclerosis Supplements</i> , 2014, 15, 33-45.	1.2	27
46	Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of Lipidologist. <i>Journal of Clinical Lipidology</i> , 2016, 10, 680-681.	1.5	25
47	Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). <i>American Journal of Cardiology</i> , 2017, 120, 931-939.	1.6	25
48	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1647-1650.	2.4	23
49	Recent advances in the treatment of homozygous familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2013, 24, 288-294.	2.7	20
50	Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International Cholesterol management Practice Study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 594-600.	1.5	17
51	PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. <i>Vascular Health and Risk Management</i> , 2016, 12, 185.	2.3	16
52	CEPHEUS SA : a South African survey on the undertreatment of hypercholesterolaemia : cardiovascular topics. <i>Cardiovascular Journal of Africa</i> , 2011, 22, 234-240.	0.4	16
53	Prevalence of dyslipidaemia in statin-treated patients in South Africa : results of the DYSlipidaemia International Study (DYSIS). <i>Cardiovascular Journal of Africa</i> , 2013, 24, 330-338.	0.4	16
54	LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. <i>Atherosclerosis</i> , 2018, 277, 327-333.	0.8	12

#	ARTICLE	IF	CITATIONS
55	Severe hypertriglyceridemia in a patient with lupus. <i>American Journal of Medicine</i> , 2005, 118, 443-444.	1.5	9
56	COVID-19 Associated Graft Loss From Renal Infarction in a Kidney Transplant Recipient. <i>Kidney International Reports</i> , 2021, 6, 1166-1169.	0.8	9
57	Management of low-density lipoprotein cholesterol levels in South Africa: the International Cholesterol management Practice Study (ICLPS). <i>Cardiovascular Journal of Africa</i> , 2019, 30, 15-23.	0.4	9
58	Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). <i>Journal of Clinical Lipidology</i> , 2008, 2, 418-425.	1.5	7
59	Evolocumab in Hyperlipidemia. <i>New England Journal of Medicine</i> , 2014, 371, 876-878.	27.0	7
60	Effects of evolocumab therapy and low LDL levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00123.	2.4	7
61	A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. <i>Advances in Therapy</i> , 2022, 39, 1857-1870.	2.9	7
62	Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice. <i>Atherosclerosis</i> , 2018, 277, 470-476.	0.8	6
63	PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 840-854.	1.2	6
64	Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia. <i>JACC Basic To Translational Science</i> , 2019, 4, 425-427.	4.1	5
65	Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 934-943.	2.4	5
66	Anacetrapib in familial hypercholesterolaemia: pros and cons. <i>Lancet, The</i> , 2015, 385, 2124-2126.	13.7	4
67	LONG-TERM SAFETY AND EFFICACY OF LOMITAPIDE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: THREE-YEAR DATA FROM THE LOMITAPIDE OBSERVATIONAL WORLDWIDE EVALUATION REGISTRY (LOWER). <i>Journal of the American College of Cardiology</i> , 2018, 71, A168.	2.8	4
68	Evolocumab for the treatment of homozygous familial hypercholesterolaemia. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 789-798.	0.8	3
69	Abstract 12450: Long-Term Efficacy and Safety of Lomitapide for the Treatment of Homozygous Familial Hypercholesterolemia: Results of the Phase 3 Extension Trial. <i>Circulation</i> , 2015, 132, .	1.6	3
70	The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. <i>Clinical Lipidology</i> , 2013, 8, 243-256.	0.4	2
71	Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study. <i>Cardiovascular Journal of Africa</i> , 2019, 30, 279-284.	0.4	2
72	Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms. <i>Current Atherosclerosis Reports</i> , 2022, , 1.	4.8	2

#	ARTICLE	IF	CITATIONS
73	Protocol for systematic review and meta-analysis: impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases. <i>BMJ Open</i> , 2020, 10, e039034.	1.9	1
74	Homozygous familial hypercholesterolemia and its treatment by inclisiran. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 197-208.	0.8	1
75	Therapeutic Management of Dyslipidemia Patients at Very High Cardiovascular Risk (CARDIO TRACK): Protocol for the Observational Registry Study. <i>JMIR Research Protocols</i> , 2018, 7, e163.	1.0	1
76	LASSA Congress, Bloemfontein, April 2011. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2011, 16, 7-7.	0.2	0